Genfit SA

Ed Arce of H.C. Wainwright maintains Buy rating on Mirum Pharmaceuticals (MIRM) with $66.00 price target, citing FDA's Breakthrough Therapy Designation for volixibat in treating cholestatic pruritus in PBC patients, and its potential to offer substantial improvement over existing therapies.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account usually reactivates within 24 hours; contact support if still disabled.